Accessibility Menu
3SBio logo

3SBio(SEHK) 1530

Market CapHK$42.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+102%
5 Year+87%
1 Year-45%
1 Month-4%
HK$16.12
-4.95%
-0.84Today
3SBio last closing stock price
MetricPriceDate
Last closeHKD 16.122026-08-31
3SBio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.94%HKD 17.902026-08-24
1 month-3.59%HKD 16.722026-07-31
3 month-4.45%HKD 16.872026-06-02
Year to date-33.33%HKD 24.182025-12-31
1 year-44.72%HKD 29.162025-08-29
3 year+145.73%HKD 6.562023-08-31
5 year+87.44%HKD 8.602021-09-01
Since inception+102.32%HKD 8.382015-06-11

3SBio Financials at a Glance

Market Cap

HK$42.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥26.88B

Net Income (TTM)

CN¥10.61B

EPS (TTM)

HK$3.65

P/E Ratio

4.54

Dividend

HK$0.00

Beta (Volatility)

-0.01 (Low)

Price

HK$16.12

Volume

34,777,452

Open

HK$16.12

Previous Close

HK$16.96

Daily Range

HK$15.94 - HK$16.84

52-Week Range

HK$14.81 - HK$36.80

Estimated Earnings Date

Mar 30, 2027

1530 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 3SBio

3SBio Inc. is a leading biotechnology company based in China, specializing in the full lifecycle of biopharmaceutical products. The company focuses on research, development, manufacturing, marketing, and sales, addressing various medical needs through its diverse portfolio of therapeutic agents.

Products and Services
  • Key products include TPIAO for thrombocytopenia and YISAIPU for autoimmune diseases
  • Offers recombinant human erythropoietins EPIAO and SEPO for anemia treatment
  • Provides additional services such as project management and technology consultation
Growth Outlook
  • Recent quarterly revenue reached CNY 13.34 billion, indicating strong market demand
  • Net income for Q4 2025 was CNY 7.12 billion, showcasing robust profitability
  • Strategic alliances with major firms enhance growth potential and market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 43.12 billion reflects consistent growth
  • Net profit margin stands at 47.93%, indicating effective cost management
  • Current ratio of 5.13 suggests strong liquidity and financial stability
3SBio Inc. has established itself as a significant player in the biotechnology sector, particularly within the People's Republic of China. The company's diverse product offerings cater to critical medical needs, ranging from oncology to autoimmune diseases. Recent financial performance highlights a strong revenue trajectory and impressive profitability metrics, positioning the company favorably for future growth. With strategic partnerships and a solid financial foundation, 3SBio Inc. is well-equipped to capitalize on emerging opportunities in the biopharmaceutical market.
AI Generated • Aug 11, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6,109

CEO

Jing Lou, PhD, EMBA

Website

www.3sbio.com

Headquarters

Shenyang, LI 110027, CN

1530 Financials

Key Financial Metrics (TTM)

Gross Margin

91.97%

Operating Margin

61.16%

Net Income Margin

46.37%

Return on Equity

30.16%

Return on Capital

35.34%

Return on Assets

23.21%

Earnings Yield

22.03%

Dividend Yield

0.00%

Payout Ratio

6.54%

Stock Overview

Market Cap

HK$42.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.50B

Volume

34.78M

Avg. Volume

33.85M

Financials (TTM)

Gross Profit

CN¥24.12B

Operating Income

CN¥13.28B

EBITDA

CN¥14.09B

Operating Cash Flow

CN¥12.94B

Capital Expenditure

-CN¥1.10B

Free Cash Flow

CN¥11.84B

Cash & ST Invst.

CN¥17.59B

Total Debt

CN¥666.81M

3SBio Performance Analysis

3SBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 7,984,013,5443.8%
20232023-12-31CNY 8,636,595,8368.2%
20242024-12-31CNY 9,875,086,90514.3%
20252025-12-31CNY 19,191,453,35394.3%
3SBio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-317.5%
Q22025-06-30-7.7%
Q42025-12-31206.3%
Q22026-06-30-66.5%
3SBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.8616.1%
20232023-12-31CNY 0.69-20.2%
20242024-12-31CNY 0.9233.1%
20252025-12-31CNY 3.72305.0%
3SBio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-11.1%
Q22025-06-3040.0%
Q42025-12-31412.5%
Q22026-06-30-84.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥4.46B

+1.7%

Gross Profit

CN¥3.74B

-1.5%

Gross Margin

83.84%

N/A

Market Cap

HK$42.42BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$6.99M

N/A

Employees

6,068

N/A

Net Income

CN¥1.13B

+3.7%

EBITDA

CN¥1.88B

+12.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥17.59B

+204.3%

Total Debt

CN¥666.81M

-84.2%

Accounts Receivable

CN¥1.15B

-7.6%

Inventory

CN¥1.04B

+26.5%

Long Term Debt

CN¥767.30M

-28.6%

Short Term Debt

CN¥619.60M

-80.3%

Return on Assets

23.21%

N/A

Return on Invested Capital

33.86%

N/A

Free Cash Flow

CN¥8.42B

+1310.6%

Operating Cash Flow

CN¥8.74B

+873.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 1530

What is the current price of 3SBio?

3SBio is trading at HK$16.12 per share.

What is the 52-week range for 3SBio?

Over the past 52 weeks, 3SBio has traded between HK$14.81 and HK$36.80.

How much debt does 3SBio have?

As of the most recent reporting period, 3SBio reported total debt of CN¥2.92B.

How much cash does 3SBio have on hand?

3SBio reported CN¥13.71B in cash and cash equivalents in its most recent financial results.

What is 3SBio’s dividend yield?

3SBio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services